The Role of the Medicinal Chemist in the Drug Discovery Process: current status and future prospects By Dr Stevan W Djuric The need for the pharmaceutical industry to produce a constant stream of new NCEs has never been more paramount but with constantly changing R&D paradigms what is the role… Read More
Applying the semantic web to drug discovery and development By Dr Eric Neumann There is much happening in drug development these days: new target classes, increasing costs, new forms of high throughput screening, and the promise of personalised medicine. But of all the issues, the one that now takes centre… Read More
High Content Screening - Emerging importance of novel reagents/probes and pathway analysis By Dr John Comley The number of high content screens will increase by 50% over the coming year; signal pathway analysis was seen as the most relevant high content screening (HCS) application; with greatest interest in applying HCS… Read More
By Dr Y. Douglas Dolginow The art and science of prediction is a risky and humiliating exercise. As bad as we are at it, predicting things remains one of the fundamental human instincts, undoubtedly linked to a Darwinian selective advantage for our species. So no matter that the umbrella was… Read More
The search for validated biomarkers in the face of biosystems complexity By Professor Ian Humphery-Smith and Will Dracup As the pharmaceutical industry is all too well aware, the genomics and postgenomic sciences have delivered an excessive number of drug targets few of which have been well validated. Indeed, apart from… Read More
Overview of biomarkers in disease, drug discovery and development By Professor Stephen Naylor The pharmaceutical industry and the healthcare sector are both confronted with expensive technological innovation, escalating costs and pointed questions about productivity and efficiency. The parallels between the problems of producing new therapeutic agents and treating patients afflicted… Read More
COX-2 Inhibitor Toxicity - Warning shot over pharma's bow By Dr Mark Schena and Dr William Greene Human beings are complex gene machines that rely on the intricate interplay of ~25,000 genes to impart biological function. Genomic function is affected by genetic variability and environmental factors, giving rise to considerable… Read More
Experimental Medicine - Developing biomarkers in early discovery to bridge preclinical and clinical development By Dr Robert Dix In today's pharmaceutical research and development environment a major problem is the transition of too many drugs to later stages of development with insufficient and/or inadequate information (eg efficacy, dosing), resulting in… Read More
Systems biology, information, disease and drug discovery By Professor Stephen Naylor Pharmaceutical companies are confronted with an urgent need to increase their lead compound and clinical candidate portfolios and to satisfy market demands for continued innovation and revenue growth. The lack of improved productivity and limited drug pipeline growth is… Read More
Leveraging the ion channel platform for lead generation in atrial fibrillation By Professor Andreas Busch Competition in the pharmaceutical industry requires a reduction in research and development project cycle times and, accordingly, an increase in productivity and efficiency. Pharmaceutical companies also are faced with the challenge of translating massive amounts… Read More
A multi-faceted approach to the advancement of cell-based drug discovery By Dr Ralph J. Garippa Cell-based assays, particularly those involving the use of microscopic imaging, are undergoing a renaissance within many pharma and biotech drug development programmes. Much of this has to do with the licensing, partnering and co-development of… Read More
Label-Free Detection - New biosensors facilitate broader range of drug discovery applications By Dr John Comley This article highlights some of the findings of a recent market report on labelfree detection trends. In particular, it looks at the current perception, main use and biggest benefit of label-free detection today. It… Read More
Tissue Microarray (TMA) - A step ahead in drug discovery By Dr CR Camozzi Estimation of the clinical importance, market size and therapy-related side-effects are key questions in drug development. The ever-rising costs of drug discovery and development ($800-1,500 million for a successful drug research project) together with demonstrated uncertainty… Read More
The Case for Multiplex Protein Assays By Dr Robert Huang and Dr Diem Nguyen Multiplex testing has gained a growing popularity among scientists, mainly due to financial and competitive pressures forcing companies to narrow their targets and validate their leads as quickly as possible. We discuss how multiplex assays can… Read More
Expanding the profile of Kinase Panels By Dr John Comley With little sign of a decline in Pharma interest in kinase targets, greater emphasis is now being directed towards kinase selectivity profiling. A recent industry market survey suggests that although the market for kinase primary screening reagents is estimated to… Read More
Functional screening of viral siRNA libraries in human primary cells By Dr Kara Bortone, Dr Frits Michiels, Dr Nick Vandeghinste, Dr Peter Tomme and Dr Helmuth van Es One of the major challenges facing the pharmaceutical industry today is the identification and validation of novel, high-quality drugable targets in underserved… Read More